COVID-19 in an international European liver transplant recipient cohort.

Becchetti, Chiara Zambelli, Marco Fabrizio Pasulo, Luisa Donato, Maria Francesca Invernizzi, Federica Detry, Olivier Dahlqvist, Géraldine [UCL] Ciccarelli, Olga [UCL] Morelli, Maria Cristina Fraga, Montserrat Svegliati-Baroni, Gianluca van Vlierberghe, Hans Coenraad, Minneke J Romero, Mario Cristobal de Gottardi, Andrea Toniutto, Pierluigi Del Prete, Luca Abbati, Claudia Samuel, Didier Pirenne, Jacques Nevens, Frederik Dufour, Jean-François COVID-LT group et al.[show all]

(eng) OBJECTIVE: Knowledge on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant recipients is lacking, particularly in terms of severity of the disease. The aim of this study was to describe the demographic, baseline clinical characteristics and early outcomes of a European cohort of liver transplant recipients with SARS-CoV-2 infection. DESIGN: We conducted an international prospective study across Europe on liver transplant recipients with SARS-CoV-2 infection confirmed by microbiological assay during the first outbreak of COVID-19 pandemic. Baseline characteristics, clinical presentation, management of immunosuppressive therapy and outcomes were collected. RESULTS: 57 patients were included (70% male, median (IQR) age at diagnosis 65 (57-70) years). 21 (37%), 32 (56%) and 21 (37%) patients had one cardiovascular disease, arterial hypertension and diabetes mellitus, respectively. The most common symptoms were fever (79%), cough (55%), dyspnoea (46%), fatigue or myalgia (56%) and GI symptoms (33%). Immunosuppression was reduced in 22 recipients (37%) and discontinued in 4 (7%). With this regard, no impact on outcome was observed. Forty-one (72%) subjects were hospitalised and 11 (19%) developed acute respiratory distress syndrome. Overall, we estimated a case fatality rate of 12% (95% CI 5% to 24%), which increased to 17% (95% CI 7% to 32%) among hospitalised patients. Five out of the seven patients who died had a history of cancer. CONCLUSION: In this European multicentre prospective study of liver transplant recipients, COVID-19 was associated with an overall and in-hospital fatality rate of 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. A history of cancer was more frequent in patients with poorer outcome.